Regional pandemic beneficiaries tanking; analysts see worst yet to come
GLOVEMAKERS in Singapore and Malaysia, as well as personal protective equipment maker Medtecs International : 546 0%, have suffered hits in terms of profitability and market values amid the easing of the coronavirus pandemic.
These counters booked record-high profit and revenue figures during the height of the pandemic. Their share prices rose as new virus variants were discovered and investors piled into the stocks.
But with the roll-out of vaccines and easing of restrictions on capacity limits and group sizes, the prospects for these companies are dimming.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Cordlife served letter of demand, notice of claim from customers
Indonesia’s Vidio is aiming to double subscribers ahead of IPO
DBS Q1 profit up 15% to S$2.95 billion; interim dividend at S$0.54 per share
KKR’s earnings rise 20% on strong management fees, annuities business
Stocks to watch: DBS, Olam, Parkway Life Reit, Japfa, CSE Global